Wave Life Sciences - WVE Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" WVE shares.
View WVE analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year price objectives for Wave Life Sciences' shares. Their WVE share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 128.6% from the stock's current price.
View analysts price targets for WVE or view top-rated stocks among Wall Street analysts.

Wave Life Sciences' stock was trading at $3.14 on January 1st, 2022. Since then, WVE shares have increased by 11.5% and is now trading at $3.50.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our WVE earnings forecast.

Wave Life Sciences Ltd. (NASDAQ:WVE) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.52. The firm earned $36.42 million during the quarter, compared to the consensus estimate of $10.70 million. Wave Life Sciences had a negative trailing twelve-month return on equity of 515.04% and a negative net margin of 297.98%. During the same quarter in the prior year, the company posted ($0.86) EPS.

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (7.23%), Artal Group S.A. (4.90%), FMR LLC (2.02%), Platinum Investment Management Ltd. (1.85%), Millennium Management LLC (1.76%) and Laurion Capital Management LP (1.42%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Kyle Moran, Michael A Panzara, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends.

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WVE stock can currently be purchased for approximately $3.50.

Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $214.37 million and generates $40.96 million in revenue each year. The company earns $-122,250,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

The company employs 235 workers across the globe.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.